X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The grant supports a meaningful portion of the Phase 3 clinical development of dabocemagene autoficel (FCX-007, D-Fi), an investigational gene therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
Lead Product(s): Dabocemagene Autoficel
Therapeutic Area: Genetic Disease Product Name: FCX-007
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: U.S. Food & Drug Administration
Deal Size: $1.8 million Upfront Cash: Undisclosed
Deal Type: Funding October 21, 2021
Details:
first patient has been dosed in the DeFi-RDEB Phase 3 clinical trial evaluating debcoemagene autoficel (D-Fi), the company’s lead gene therapy candidate formerly designated FCX-007, in recessive dystrophic epidermolysis bullosa (RDEB).
Lead Product(s): Dabocemagene Autoficel
Therapeutic Area: Genetic Disease Product Name: FCX-007
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
The company plans to use the funding to advance and expand its gene therapy pipeline, led by the Phase 3 clinical development of FCX-007.
Lead Product(s): Dabocemagene Autoficel
Therapeutic Area: Genetic Disease Product Name: FCX-007
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Fidelity Management & Research Company
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
